Ze Wang

Dr. Ze Wang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2026 in Biomaterials
Verified
Journal Article
Closed access
LLLei Li
Lei Li
ALAnnan Liu
Annan Liu
ZWZe Wang
Ze Wang
HLHao Liang
Hao Liang
AWAndrew K. Whittake
Andrew K. Whittake
QLQuan Lin
Quan Lin

11 May 2025 in Journal of Colloid and Interface Science
Verified
Journal Article
Closed access
ALAnnan Liu
Annan Liu
JLJianwen Li
Jianwen Li
WQWenrui Qu
Wenrui Qu
BYBoyu Yang
Boyu Yang
XLXingchen Li
Xingchen Li
QLQuan Lin
Quan Lin

20 January 2026 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
ALAnnan Liu
Annan Liu
LLLei Li
Lei Li
BYBin Yang
Bin Yang
KJKejun Jiang
Kejun Jiang
HLHao Liang
Hao Liang
QLQuan Lin
Quan Lin

18 September 2025 in Materials Today Bio
Verified
Journal Article
Open access
LHLiang He
Liang He
HLHao Liang
Hao Liang
JWJixue Wang
Jixue Wang
ALAnnan Liu
Annan Liu
LLLei Li
Lei Li
QLQuan Lin
Quan Lin
Metastasis prostate cancer (PCa) precision detection and effective treatment remain significant challenge in clinic. Ferroptosis brought promising therapeutic strategy for the treatment of metastatic PCa, effectively inducing ferroptosis in PCa cells represents key to improve therapeutic efficacy. Herein, we developed a multifunctional nanoplatform Fe/Au nanodots-bombesin (FGN-BBN) as the ferroptosis nano-inducer to generate large amount of ROS to induce ferroptosis through an "open-source throttling" strategy for targeted imaging-guided therapy of metastatic PCa. On the one hand, FGN-BBN serves as an efficient biomimetic nanozyme and photothermal agent, exhibiting great POD-like activity and generating abundant reactive oxygen species (ROS) via photothermal-enhanced chemodynamic therapy (CDT) to induce ferroptosis, which is achieving "open source" aspect. On the other hand, FGN-BBN exhibit GPx-like activity that depletes overexpressed glutathione (GSH) within the tumor microenvironment, thereby preventing the neutralization of ROS and achieving the "throttling" effect. Furthermore, bombesin facilitates targeted delivery of the nanozyme to metastatic PCa cells, synergistically enhancing ferroptosis activity. In terms of diagnosis, FGN-BBN possesses targeted recognition capabilities and enables multimode bioimaging including fluorescence (FL), computed tomography (CT), and magnetic resonance imaging (MRI), allowing for the "visualization" of tumor localization and real-time imaging-guided therapy. In summary, the multifunctional nanoplatform integrates multienzyme activity, targeted recognition, multimodal imaging, photothermal therapy, and CDT to induce high-efficiency ferroptosis, offering an effective theranostic strategy for metastatic PCa.